{"id":"W3122624214","doi":"10.1016/s0140-6736(20)32554-x","title":"Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial","year":2021,"lang":"en","type":"article","venue":"The Lancet","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":211,"is_retracted":false,"has_abstract":false,"ca_institutions":"Ontario Institute for Cancer Research; Cancer Care Ontario; Kelowna General Hospital; Ottawa Regional Cancer Foundation; Princess Margaret Cancer Centre","funders":"National Cancer Institute; Genentech; Astellas Pharma; Ontario Institute for Cancer Research; Incyte; Ipsen; Syndax Pharmaceuticals; Clovis Oncology; Astex Pharmaceuticals; Regeneron Pharmaceuticals; U.S. Department of Defense; Princess Margaret Cancer Foundation; Sanofi; GlaxoSmithKline; Celgene; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Medicine; Internal medicine; Gemcitabine; Population; Ovarian cancer; Placebo; Clinical trial; Clinical endpoint; Oncology; Cancer; Surgery; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001875885,0.002652403,0.004888144,0.0006482889,0.0005022678,0.001525334,0.001106071,0.00301313,0.009343158],"category_scores_gemma":[0.00216117,0.001186155,0.002684701,0.0006094098,0.001421526,0.001503041,0.0006105644,0.004186555,0.001576952],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008470701,"about_ca_system_score_gemma":0.001149198,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001214029,"about_ca_topic_score_gemma":0.002916129,"domain_scores_codex":[0.9992943,0.0003505943,0.00004824019,0.0001522414,0.00004635632,0.0001082859],"domain_scores_gemma":[0.9991717,0.0002822447,0.0001625794,0.00007418587,0.00004751229,0.0002618046],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9886327,0.001851336,0.0001161148,0.000754641,0.0007075596,0.00002091675,0.00002685674,0.0001494671,0.001021633,0.00006357357,0.0004801914,0.006174845],"study_design_scores_gemma":[0.9848472,0.01410621,0.0002573854,0.00002366635,0.0002139544,0.00001125091,0.000008533099,0.00009873852,0.00007973071,0.00006488245,0.0002812509,0.000007093272],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9604375,0.0198375,0.001371377,0.001715272,0.003219755,0.007263693,0.002197635,0.0003072655,0.003649999],"genre_scores_gemma":[0.9600475,0.01227487,0.002924047,0.002835001,0.001396216,0.008766701,0.001880012,0.00007598388,0.009799712],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009343158,"threshold_uncertainty_score":0.03125596,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0907230657683899,"score_gpt":0.371654976859516,"score_spread":0.2809319110911261,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}